S100B is a calcium-binding protein mainly expressed by astrocytes, but also localized in other definite neural and extra-neural cell types. While its presence in biological fluids is widely recognized as a reliable biomarker of active injury, growing evidence now indicates that high levels of S100B are suggestive of pathogenic processes in different neural, but also extra-neural, disorders. Indeed, modulation of S100B levels correlates with the occurrence of clinical and/or toxic parameters in experimental models of diseases such as Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, muscular dystrophy, multiple sclerosis, acute neural injury, inflammatory bowel disease, uveal and retinal disorders, obesity, diabetes and cancer, thus directly linking the levels of S100B to pathogenic mechanisms. In general, deletion/inactivation of the protein causes the improvement of the disease, whereas its over-expression/administration induces a worse clinical presentation. This scenario reasonably proposes S100B as a common therapeutic target for several different disorders, also offering new clues to individuate possible unexpected connections among these diseases.

Michetti, F., Di Sante, G., Clementi, M. E., Sampaolese, B., Casalbore, P., Volonté, C., Romano Spica, V., Paolo Parnigotto, P., Di Liddo, R., Amadio, S., Ria, F., Growing role of S100B protein as a putative therapeutic target for neurological -and nonneurological- disorders, <<NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS>>, 2021; (2021): N/A-N/A [http://hdl.handle.net/10807/178710]

Growing role of S100B protein as a putative therapeutic target for neurological -and nonneurological- disorders

Michetti, Fabrizio;Di Sante, Gabriele;Clementi, Maria Elisabetta;Ria, Francesco
Ultimo
2021

Abstract

S100B is a calcium-binding protein mainly expressed by astrocytes, but also localized in other definite neural and extra-neural cell types. While its presence in biological fluids is widely recognized as a reliable biomarker of active injury, growing evidence now indicates that high levels of S100B are suggestive of pathogenic processes in different neural, but also extra-neural, disorders. Indeed, modulation of S100B levels correlates with the occurrence of clinical and/or toxic parameters in experimental models of diseases such as Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, muscular dystrophy, multiple sclerosis, acute neural injury, inflammatory bowel disease, uveal and retinal disorders, obesity, diabetes and cancer, thus directly linking the levels of S100B to pathogenic mechanisms. In general, deletion/inactivation of the protein causes the improvement of the disease, whereas its over-expression/administration induces a worse clinical presentation. This scenario reasonably proposes S100B as a common therapeutic target for several different disorders, also offering new clues to individuate possible unexpected connections among these diseases.
Inglese
Michetti, F., Di Sante, G., Clementi, M. E., Sampaolese, B., Casalbore, P., Volonté, C., Romano Spica, V., Paolo Parnigotto, P., Di Liddo, R., Amadio, S., Ria, F., Growing role of S100B protein as a putative therapeutic target for neurological -and nonneurological- disorders, <<NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS>>, 2021; (2021): N/A-N/A [http://hdl.handle.net/10807/178710]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/178710
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact